a termination fee of $600,000 may be payable by Rallybio to Avenzo if (i)(a) the Merger Agreement is terminated because the Merger has not been consummated by the End Date
On March 1, 2026, Rallybio entered into an Agreement and Plan of Merger and Reorganization with Candid pursuant to which the parties intended to undertake a business combination.
Candid and UCB, on behalf of themselves and their respective affiliates, agreed to release Parent and its affiliates from all claims in respect of the Merger Agreement, the Contemplated Transactions …
Candid and UCB, on behalf of themselves and their respective affiliates, agreed to release Parent and its affiliates from all claims in respect of the Merger Agreement, the Contemplated Transactions …
we entered into an agreement with Sobi, pursuant to which we acquired the right, title and interest in assets related to certain C5 inhibitor compounds.
any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shal…
Reciprocal relationship from JNJ graph: Reciprocal relationship from RLYB graph: any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the…
any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shal…
Reciprocal relationship from SNYNF graph: Reciprocal relationship from RLYB graph: any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing t…
The Company recognized revenue of $ 0.2 million for both the three months ended March 31, 2026 and 2025, related to data collection and data submission with the identified performance obligations, an…
Pursuant to the Subscription Agreement, and subject to the terms and conditions therein, Avenzo agreed to sell, and the Investors agreed to purchase, immediately prior to the Effective Time, shares o…
any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shal…
Reciprocal relationship from JNJ graph: Reciprocal relationship from RLYB graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from RLYB graph: any sublicenses) will terminate and (…
ompany determined that the J&J Collaboration Agreement is not in the scope of ASC 808. Asset Acquisition In May 2022, we obtained worldwide exclusive rights to RLYB331, with Kymab Limited ("Sanofi") …
Reciprocal relationship from SNYNF graph: Reciprocal relationship from RLYB graph: ompany determined that the J&J Collaboration Agreement is not in the scope of ASC 808. Asset Acquisition In May 2022…
Rallybio Corporation Debt Obligations
Instrument
Description
Confidence
Evidence
RLYB-DEBT
Debt stack $154,000
90%
Market cache reports total debt of $154,000.
Rallybio Corporation Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Rallybio Corporation.
Rallybio Corporation Ownership
Holder
Name
Confidence
Evidence
RLYB-OWNER-JOHNSON-JOHNSON
JOHNSON & JOHNSON
90%
13F overlay lists JOHNSON & JOHNSON as top holder; 3 tracked holders.
